Pharma Exempt From US Tariffs, Providing Reprieve For Indian Pharma Cos
Indian Pharma Cos 10-50% Sales From The US
Tariff Discussion On Pharma May Resurface
Don't Expect Unmanageable Tariffs For Indian Pharma Sector Ahead
For Key Indian Cos, Having Mfg Plants In Us Provides Further Cushion Against Any Dvpts